NYXH VS OPT Stock Comparison

Performance

NYXH
10/100

NYXH returned -15.83% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

OPT
10/100

OPT returned -69.46% in the last 12 months. Based on SPY's performance of -13.12%, its performance is below average giving it a score of 10 of 100.

Technicals

NYXH
14/100

NYXH receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

OPT
36/100

OPT receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.

Earnings

NYXH
10/100

NYXH has missed earnings 5 times in the last 20 quarters.

OPT

"Earnings" not found for OPT

Profit

NYXH
10/100

Out of the last 13 quarters, NYXH has had 0 profitable quarters and has increased their profits year over year on 0 of them.

OPT
10/100

Out of the last 20 quarters, OPT has had 1 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

NYXH
45/100

NYXH has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

OPT
33/100

OPT has had a lower than average amount of volatility over the last 12 months giving it a score of 32 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Nyxoah SA Ordinary Shares Summary

Nasdaq / NYXH

Healthcare

Medical - Instruments & Supplies

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Opthea Limited American Depositary Shares Summary

Nasdaq / OPT

Healthcare

Biotechnology

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Power up your portfolio